[go: up one dir, main page]

WO2023122663A3 - Effector proteins and methods of use - Google Patents

Effector proteins and methods of use Download PDF

Info

Publication number
WO2023122663A3
WO2023122663A3 PCT/US2022/082137 US2022082137W WO2023122663A3 WO 2023122663 A3 WO2023122663 A3 WO 2023122663A3 US 2022082137 W US2022082137 W US 2022082137W WO 2023122663 A3 WO2023122663 A3 WO 2023122663A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
effector proteins
proteins
systems
effector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2022/082137
Other languages
French (fr)
Other versions
WO2023122663A2 (en
Inventor
Lucas Benjamin HARRINGTON
Benjamin Julius RAUCH
Aaron DELOUGHERY
Alexander Richard NECKELMANN
Timothy Robert ABBOTT
William Douglass WRIGHT
Yuxuan Zheng
David Burstein
Dov Arie GERTZ
Tomer PARKIET
Fnu YUNANDA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Mammoth Biosciences Inc
Original Assignee
Ramot at Tel Aviv University Ltd
Mammoth Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd, Mammoth Biosciences Inc filed Critical Ramot at Tel Aviv University Ltd
Publication of WO2023122663A2 publication Critical patent/WO2023122663A2/en
Publication of WO2023122663A3 publication Critical patent/WO2023122663A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Provided herein are compositions, systems, and methods comprising effector proteins and uses thereof. These effector proteins may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure may leverage the activities of these effector proteins for the modification, detection, and engineering of nucleic acids.
PCT/US2022/082137 2021-12-23 2022-12-21 Effector proteins and methods of use Ceased WO2023122663A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163293443P 2021-12-23 2021-12-23
US63/293,443 2021-12-23
US202263321624P 2022-03-18 2022-03-18
US63/321,624 2022-03-18
US202263353469P 2022-06-17 2022-06-17
US63/353,469 2022-06-17

Publications (2)

Publication Number Publication Date
WO2023122663A2 WO2023122663A2 (en) 2023-06-29
WO2023122663A3 true WO2023122663A3 (en) 2023-08-03

Family

ID=86903769

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/082137 Ceased WO2023122663A2 (en) 2021-12-23 2022-12-21 Effector proteins and methods of use

Country Status (1)

Country Link
WO (1) WO2023122663A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020168291A1 (en) * 2019-02-14 2020-08-20 Metagenomi Ip Technologies, Llc Enzymes with ruvc domains
US20200399697A1 (en) * 2017-11-22 2020-12-24 The Regents Of The University Of California Type v crispr/cas effector proteins for cleaving ssdnas and detecting target dnas
US20210130827A1 (en) * 2019-10-30 2021-05-06 Pairwise Plants Services, Inc. Type v crispr-cas base editors and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200399697A1 (en) * 2017-11-22 2020-12-24 The Regents Of The University Of California Type v crispr/cas effector proteins for cleaving ssdnas and detecting target dnas
WO2020168291A1 (en) * 2019-02-14 2020-08-20 Metagenomi Ip Technologies, Llc Enzymes with ruvc domains
US20210130827A1 (en) * 2019-10-30 2021-05-06 Pairwise Plants Services, Inc. Type v crispr-cas base editors and methods of use thereof

Also Published As

Publication number Publication date
WO2023122663A2 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
WO2023102329A3 (en) Effector proteins and uses thereof
EP4257696A3 (en) Novel crispr dna targeting enzymes and systems
WO2020030984A3 (en) Compositions and methods for genome engineering with cas12a proteins
EP4632066A3 (en) Class ii, type ii crispr systems
EP4403638A3 (en) Novel crispr enzymes and systems
WO2022140577A3 (en) Compositions and methods for epigenetic editing
EP4524236A3 (en) Anti-vegf protein compositions and methods for producing the same
WO2023141590A3 (en) Effector proteins and methods of use
WO2004022701A3 (en) Exponential amplification of nucleic acids using nicking agents
EP2270042A3 (en) KDR peptides and vaccines comprising the same
WO2023191858A3 (en) Nanoelectric devices and use thereof
WO2018081592A3 (en) Compositions and methods for the production of compounds
WO2024015881A3 (en) Compositions, systems, and methods for targeted transcriptional activation
EP4491635A3 (en) Anti-ccr8 antibodies
WO2022241059A3 (en) Effector proteins and methods of use
WO2021108442A3 (en) Modulators of cas9 polypeptide activity and methods of use thereof
WO2024138202A3 (en) Effector proteins, compositions, systems and methods of use thereof
WO2023250384A3 (en) Crispr-cas effector polypeptides and methods of use thereof
WO2023220649A3 (en) Effector protein compositions and methods of use thereof
CA3264877A1 (en) Rna-triggered protein cleavage and applications by the crispr cas7-11-csx29 complex
WO2023122663A3 (en) Effector proteins and methods of use
WO2024006824A3 (en) Effector proteins, compositions, systems and methods of use thereof
WO2024192211A3 (en) Effector proteins and uses thereof
WO2023077095A3 (en) Effector proteins, compositions, systems, devices, kits and methods of use thereof
WO2024163519A3 (en) Effector proteins, compositions, systems and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22912698

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22912698

Country of ref document: EP

Kind code of ref document: A2